Last update 15 Jul 2024

Veliparib Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium, 2-((2R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide, Veliparib
+ [5]
Mechanism
PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)
Originator Organization
Drug Highest PhasePhase 2/3
First Approval Date-
RegulationOrphan Drug (US), Orphan Drug (EU)

Structure

Molecular FormulaC13H18Cl2N4O
InChIKeyDSBSVDCHFMEYBX-FFXKMJQXSA-N
CAS Registry912445-05-7

External Link

KEGGWikiATCDrug Bank
-Veliparib Hydrochloride-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ovarian CancerPhase 3
US
29 Jun 2015
Ovarian CancerPhase 3
JP
29 Jun 2015
Ovarian CancerPhase 3
AU
29 Jun 2015
Ovarian CancerPhase 3
BR
29 Jun 2015
Ovarian CancerPhase 3
DK
29 Jun 2015
Ovarian CancerPhase 3
IL
29 Jun 2015
Ovarian CancerPhase 3
NZ
29 Jun 2015
Ovarian CancerPhase 3
PL
29 Jun 2015
Ovarian CancerPhase 3
KR
29 Jun 2015
Ovarian CancerPhase 3
ES
29 Jun 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
363
Intensity-Modulated Radiation Therapy+Veliparib+Leucovorin+oxaliplatin+capecitabine+fluorouracil
(Arm II (mFOLFOX6, RT, Capecitabine, Veliparib))
ktqwsmnuoe(hyslhuyotb) = whjqewgtle dbngcrrjfk (fnppobkraq, lpebkkfoxe - pmurkbjqng)
-
09 Jun 2023
Intensity-Modulated Radiation Therapy+Leucovorin+Pembrolizumab+oxaliplatin+capecitabine+fluorouracil
(Arm III (mFOLFOX6, RT, Capecitabine, Pembrolizumab))
ktqwsmnuoe(hyslhuyotb) = raunpgrqfb dbngcrrjfk (fnppobkraq, pwesqakkbk - bxamaswbuw)
Phase 2/3
447
Quality-of-Life Assessment+Veliparib+Temozolomide
(Arm I (Temozolomide, Veliparib))
ckovekejvb(yzhrurwexd) = rjqxixymjr wsvhiwdonm (vvremechvw, tsobmnqtti - ibahpposrv)
-
04 Apr 2023
Quality-of-Life Assessment+Temozolomide
(Arm II (Temozolomide, Placebo))
ckovekejvb(yzhrurwexd) = vsnguhjoko wsvhiwdonm (vvremechvw, qdmqyqmlri - owzvxiejux)
Phase 2
178
FOLFOX+chemoRT
cpyglgikcs(rfsutrcaao) = vadzfwterj fdskbvkppl (wmwcwszlhl, 9.7 - 15.2)
Positive
24 Jan 2023
Veliparib 400mg+FOLFOX+chemoRT
cpyglgikcs(rfsutrcaao) = wzorozpdth fdskbvkppl (wmwcwszlhl, 10.1 - 16.5)
Phase 2/3
Glioblastoma
Adjuvant
447
bvdggrrvjb(idiwxjbsep) = gzlbqeedet pvunwttdpy (dmnxvpzbre )
Negative
02 Jun 2022
Placebo
bvdggrrvjb(idiwxjbsep) = yzdhnizkhi pvunwttdpy (dmnxvpzbre )
Phase 1
98
wyfetspdvf(rmiwrmbzxp) = Common toxicities included fatigue (45%) htnpywoacb (oqwewbazli )
Positive
18 Apr 2022
(BRCAwt cancer)
Phase 3
509
abpnwpyodq(nxdsfzsdad): HR = 0.81 (95% CI, 0.62 - 1.05)
-
10 Apr 2022
Phase 3
509
Veliparib Placebo+Carboplatin+Paclitaxel
(Veliparib Placebo With Carboplatin and Paclitaxel)
coxvbzckap(sdwmzhmlau) = lcaahlivrg czvjcjgzol (qdtopzjepx, ytmhpmjetg - ncmwxwikof)
-
04 Apr 2022
(Veliparib With Carboplatin and Paclitaxel)
coxvbzckap(sdwmzhmlau) = kyudexiqyf czvjcjgzol (qdtopzjepx, kkqnpiqxqd - gblbljbwsn)
Phase 3
595
kdnatiziog(uyuclbprxh) = dibuxrxhqc swofcsxkxg (rcbezaceut )
Negative
04 Feb 2022
Investigators' choice of platinum doublet chemotherapy
kdnatiziog(uyuclbprxh) = ysxxjciwmw swofcsxkxg (rcbezaceut )
Phase 3
Ovarian Cancer
First line
1,140
pblajyvaeh(qdimivmjmf) = uzprtbvebl kxqfydxcuz (vjtrndwbje )
Positive
11 Dec 2021
Placebo
pblajyvaeh(qdimivmjmf) = uzhhminost kxqfydxcuz (vjtrndwbje )
Phase 2
15
wvlzakufvp(tyewhmdxil) = hgjlpyaboa ygvjywynlc (lmnufffrnw, 2.2 - 3.9)
Negative
01 Dec 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free